Microbiome Power Play: Novonesis and Biocodex Deepen Strategic Alliance

COPENHAGEN, Denmark – April 23, 2026 – In a significant move poised to reshape the competitive landscape of microbiome health, PrecisionBiotics®, the specialist microbiome unit of Novonesis, has renewed and expanded its strategic partnership with the French pharmaceutical group Biocodex. The new agreement, formalized at a leadership summit, marks the next phase of a nine-year collaboration, signaling a deeper alignment to accelerate growth and innovation in the rapidly expanding global probiotics sector.

This isn't just a routine renewal; it's a strategic doubling-down by two industry heavyweights. The partnership combines the cutting-edge bioscience of Novonesis—a global leader formed from the 2024 merger of Novozymes and Chr. Hansen—with Biocodex's formidable international market presence and distribution network spanning over 100 countries. The collaboration has already proven its value, and this next chapter aims to solidify their joint leadership in a market projected to surge from USD 72.2 billion in 2026 to over USD 111 billion by 2033.

"Over the past nine years, our partnership with Biocodex has demonstrated what can be achieved when strong science is combined with deep market expertise," said Cris Burson-Thomas, a Regional Director for Consumer Health at Novonesis. "As we enter this next phase together, we are excited to build on that foundation; expanding access to clinically proven microbiome solutions and continuing to set the standard for innovation in this space."

Echoing this sentiment, Biocodex CEO Nicolas Coudurier stated, "This strengthened partnership with Novonesis, our long-standing partner, marks an important step for Biocodex. It reinforces our strategic focus on microbiota and our ambition to accelerate growth and innovation with a key leader in microbiome science, to bring high-quality, evidence-based solutions to more patients worldwide."

The Science Behind the Success: Alflorex® and Beyond

At the heart of the partnership's success is Alflorex®, PrecisionBiotics’ flagship probiotic product. Containing the unique and clinically researched Bifidobacterium longum 35624™ strain, Alflorex® has become a leading solution for managing symptoms of Irritable Bowel Syndrome (IBS). Since its 2014 launch, Biocodex's distribution has propelled the product to leading positions in several key European markets and availability in more than 15 countries.

The product's efficacy hinges on its single-strain approach, which research suggests can be more effective than multi-strain cocktails where different bacteria may compete. The 35624™ strain works by adhering to the intestinal wall, helping to strengthen the gut barrier and soothe irritation—a targeted mechanism that resonates with both clinicians and consumers seeking evidence-based solutions.

This scientific rigor is emblematic of the Novonesis strategy. The 2020 acquisition of PrecisionBiotics for €80 million was a deliberate move to bolster its human health division, leveraging a "Strain to Solution" approach that guides products from lab ideation to consumer-ready formulations. Now integrated into the larger Novonesis entity, PrecisionBiotics has access to one of the world's largest collections of bacterial strains and enzymes. This vast biological toolbox is fueling research into new frontiers, including the gut-brain axis and synbiotic solutions for metabolic health, the latter through a notable research collaboration with pharmaceutical giant Novo Nordisk.

A Blueprint for a Billion-Dollar Market

The renewed alliance is a masterclass in symbiotic partnership, leveraging complementary strengths to navigate a fiercely competitive market where giants like Nestlé Health Science and Danone hold significant sway. Novonesis provides the deep scientific innovation and R&D engine, while Biocodex delivers the market access, regulatory know-how, and commercial infrastructure essential for global scale.

Biocodex is far more than a simple distributor. The independent company, which posted sales of €501 million in 2022, is a pioneer in microbiota research in its own right, having launched the world's first probiotic drug, Saccharomyces boulardii CNCM I-745®, back in 1953. Its corporate strategy rests on three pillars: microbiota care, women's health, and orphan diseases. This diversified focus provides a stable and synergistic platform for the PrecisionBiotics partnership.

The company's commitment to the microbiome field is extensive, from funding academic research through the Biocodex Microbiota Foundation to investing in innovative startups like MaaT Pharma, which focuses on fecal microbiota transplantation. This deep-seated expertise makes Biocodex a strategic peer, not just a channel partner, creating a foundation of shared ambition that has sustained the collaboration for nearly a decade.

Navigating a Complex Global Regulatory Maze

Perhaps the most critical, yet least visible, aspect of this strengthened alliance is its potential to navigate the fragmented and challenging regulatory environment for probiotics. The path to market is fraught with complexity, particularly in the European Union, a key territory for Alflorex®.

The European Food Safety Authority (EFSA) maintains an exceptionally strict position, treating the very term "probiotic" as a health claim that requires authorization. To date, nearly all such claims have been rejected due to what the agency deems insufficient scientific substantiation, creating a major hurdle for brands trying to communicate the benefits of their products. This has led to a frustrating situation where a product's science may be robust, but its marketing language is severely restricted. While some member states like Italy have carved out exceptions, the lack of a harmonized EU-wide approach remains a significant barrier to growth.

In contrast, the United States regulates probiotics primarily as dietary supplements, allowing for a more permissive, though still complex, claims environment. This global patchwork of regulations demands deep, localized expertise. By deepening its ties with Biocodex, Novonesis secures a partner with decades of experience navigating these disparate legal frameworks across Europe and beyond. This expertise is invaluable for ensuring compliance, securing market authorization, and effectively tailoring commercial strategies to each unique region, turning a potential obstacle into a shared competitive advantage.